Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSK 692342
- Development stage
- Unknown
- Lead developer
- Gates Medical Research Institute
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
GSK 692342 is an investigational mRNA-based vaccine candidate developed by GSK for the prevention of tuberculosis (TB). Utilizing mRNA technology, the vaccine is designed to deliver genetic instructions to host cells to express specific antigens derived from *Mycobacterium tuberculosis*, thereby eliciting a targeted adaptive immune response involving both T-cell and B-cell activation. This candidate represents a strategic expansion of GSK's mRNA platform into the field of infectious diseases beyond respiratory viruses. It is currently being evaluated in Phase 2 clinical trials (such as NCT05554289) to characterize its safety profile, immunogenicity, and the kinetics of mRNA expression in healthy adult populations.
- Other names
- GSK 692342 tuberculosis vaccineGSK692342 tuberculosis vaccineGSK-692342 tuberculosis vaccineGSK 692342 TB vaccineGSK692342 TB vaccineGSK-692342 TB vaccine
Beyond the preview
Go deeper on GSK 692342.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GSK 692342.